CSL inked an agreement to use Xencor’s XmAb® technology platform to enhance the ADCC effector function of its therapeutic antibodies. In addition to an upfront payment, CSL will pay Xencor development milestone payments and product royalties for each product commercialized that incorporates the Xencor technology.
During the research phase of the collaboration, Xencor will provide CSL the ability to use this technology across its antibody candidate pipeline. Xencor has granted CSL several commercial licenses to move product candidates that incorporate XmAb technology into development and ultimately commercialization.
